Immunai
Last updated: May 4, 2026
Immunai is an Israeli-founded AI-biotech platform combining single-cell immunology data, proprietary machine learning (ImmunoDynamics Engine), and functional validation to accelerate pharmaceutical target discovery, preclinical candidate prioritization, and clinical trial optimization.
Visit WebsiteCompany Overview
Immunai's core platform integrates multi-omic single-cell analysis (whole transcriptome, proteomics, TCR/BCR repertoire, spatial transcriptomics) with a proprietary AMICA database containing harmonized data from over 300,000 patient samples across 500+ diseases and 800+ characterized cell types. The company's ImmunoDynamics Engine (IDE) is a machine learning framework designed to extract immune mechanistic signals and link them to clinical treatment responses and therapeutic outcomes. This enables three primary product applications: (1) target discovery to identify novel, high-impact disease-linked therapeutic targets; (2) preclinical evaluation to prioritize drug candidates and predict efficacy/safety profiles; and (3) clinical trial optimization via patient stratification and mechanism-of-action assessment.
Immunai's commercial traction includes partnerships with tier-1 pharmaceutical firms. Published examples include a partnership with AstraZeneca for inflammatory bowel disease (IBD) target discovery and collaboration with Teva for vitiligo mechanism elucidation and biomarker discovery in support of Teva's IL-15 targeted antibody program. These partnerships validate demand for immune intelligence in complex, high-value therapeutic domains where immune dysregulation drives disease pathogenesis. The company operates with dual headquarters in Tel Aviv (Israel) and New York, blending Israeli deep-tech biotech development with North American pharma commercialization expertise.
The immunology-focused AI-biotech market remains immature and competitive but strategically high-value due to rising pharma interest in precision immunology, personalized medicine, and biomarker-driven clinical trial design. Immunai's differentiation rests on immune-specific platform architecture (rather than generic computational biology), validated partnerships, and proprietary AMICA data depth. Competitors include generalist platforms (Recursion, Schrodinger) with immunology modules, specialist single-cell analytics vendors (insitro), and emerging immune-focused startups. Long biotech sales cycles, validation requirements, and scientific/translational complexity remain material headwinds.
From a defense-adjacent strategic perspective, immune intelligence platforms have limited direct dual-use potential. While immune system biology and biodefense preparedness are related domains (e.g., understanding pathogen immune evasion, vaccine immunogenicity, or immune-mediated disease resilience), Immunai's platform is purpose-built for therapeutic target and biomarker discovery in civilian drug development. The platform's architecture, data, and business model show no evidence of dual-use targeting or national-security application. Immunai is strategically relevant for deep-tech biotech portfolios but the dual-use thesis is attenuated—the company should be evaluated primarily on its therapeutic biotech merits and commercial market potential rather than strategic defense alignment.
Strategic Fit Assessment
Priority signal means this entry may be worth researching within the Claw & Talon thesis. It does not mean investable, suitable, endorsed, available, or likely to produce returns.
Immunai operates in the high-value therapeutic AI-biotech segment with demonstrated pharma partnerships (AstraZeneca, Teva), differentiated immune-specific platform depth (AMICA + IDE), strong technical team (Israeli biotech pedigree + US pharma commercialization capability), and Series B institutional backing. The immunology-focused AI market offers significant long-term upside as pharma accelerates precision medicine and biomarker-driven trial design adoption. Primary strategic relevance thesis is as a therapeutic biotech platform play, not a dual-use asset.
Strategic Value to U.S.-Israel Alliance
Immunai creates near-term value in target discovery and clinical trial efficiency for pharma partners, reducing time-to-market and improving candidate success probability in high-value immune-mediated disease spaces. Long-term strategic value is contingent on platform adoption, proprietary data defensibility, and eventual commercialization momentum (IPO or acquisition).
Key Technologies
- Single-cell multi-omic sequencing (RNA, proteome, TCR/BCR, spatial)
- ImmunoDynamics Engine (immune-mechanism-to-outcome machine learning model)
- AMICA proprietary harmonized immune cell database (300K+ samples, 500+ diseases)
- Functional genomics validation platform (in vitro perturbation assays)
- Clinical immune annotation and patient stratification analytics
Use Cases & Applications
- Pharmaceutical target discovery in immune-mediated diseases (IBD, autoimmune, oncology)
- Preclinical drug candidate prioritization and efficacy/safety prediction
- Clinical trial patient stratification and biomarker identification
- Mechanism-of-action understanding for therapeutic antibodies and small molecules
- Academic immunology research and disease mechanism studies
Sources and verification
This profile is based on public-source research, Claw & Talon curation, and editorial judgment. Inclusion does not imply endorsement, partnership, investment, or a recommendation to transact. Readers should still confirm current status, customers, funding, and product claims before relying on this profile.
Public sources
The links below are visible public references used for source discipline around company identity, status, funding, customer, acquisition, public-company, or other material claims where available.
- Official website Primary public reference for company identity, positioning, and current web presence.
- Profile update timestamp Last updated in the Claw & Talon database on May 4, 2026.
Investor Lens
What this entry is
Private startup
Why it may matter
Immunai may matter as a Health & BioTech entry with direct private-company diligence for Israeli technology research.
How an independent investor should read this
Direct private-company diligence. Read this profile as a starting point for independent verification, not as a recommendation or suitability assessment.
Evidence to verify
- Verify current status
- Verify traction
- Verify cap table/funding
- Verify technical claims
- Verify customer concentration
Main investor questions
- Is the company currently active, independently financeable, and raising or not raising on terms you can verify?
- What customer, revenue, product, and technical evidence supports the company story?
- What valuation, cap table, rights, and follow-on assumptions would govern any private exposure?
- What evidence would change the thesis or show that the profile is stale?
What not to infer
- Inclusion does not imply endorsement.
- Inclusion does not imply allocation availability or current fundraising.
- Scores do not indicate investment suitability or expected returns.
- Strategic importance does not automatically imply venture return potential.
Diligence questions
- What evidence verifies Immunai's current customer traction, deployment status, and revenue concentration?
- Which technical claims are independently demonstrable today, and which remain roadmap or pilot-stage assertions?
- Is there a credible national-security or public-sector use case, or is the company primarily a commercial technology asset?
- What regulatory, procurement, and buyer-adoption constraints could slow deployment in strategic or government-adjacent markets?
- What would disconfirm the priority signal: weak customer references, thin technical differentiation, poor capital efficiency, or limited allied-market access?
Related sector
See the Health & BioTech sector page for market context, related subcategories, and other Israeli companies in this part of the database.
Related companies
Need a diligence readout?
Use the profile and related checklists as a starting point. If the decision needs more context, request a company screen, founder-call prep, diligence memo, or sector readout.